Iodine I 131 Monoclonal Antibody 8H9 in Treating Patients with Desmoplastic Small Round Cell Tumors and Other Solid Tumors Involving the Peritoneum
- Patients must have the diagnosis of (a) DSRCT with peritoneal involvement or (b) other 8H9-positive solid tumors involving the peritoneum (e.g. adrenocortical carcinoma, Wilm's tumor)
- For tumors other than DSRCT, patients must have a history of tumor progression or recurrence or failure to achieve complete response with standard therapy or < 20% chance of long term disease-free survival
- For tumors other than DSRCT, 8H9 reactivity must be confirmed by immunohistochemistry
- Patients with DSCRT are not required to have measurable or evaluable disease
- Patients with tumors other than DSRCT without measurable or evaluable disease will only be considered if they have < 20% chance of long term disease-free survival
- Prior therapy: at least 4 weeks should have elapsed since any biologic therapy, or immunotherapy; three weeks should have elapsed since last dose of chemotherapy or radiotherapy
- Able to cooperate with radiation safety restrictions during therapy period
- Stem cells: patients must have an autologous hematopoietic stem cell product cryopreserved and available for re-infusion after 131I-8H9 treatment; the minimum dose for hematopoietic stem cells is 2 x 10^6 cluster of differentiation (CD)34+ cells/kg
- Minimum life expectancy of six weeks as determined by consenting professional
- Signed informed consent indicating awareness of the investigational nature of this program
- Severe major organ toxicity; renal, cardiac, hepatic, pulmonary, gastrointestinal and neurologic toxicity should all be grade 1 or less (per National Cancer Institute [NCI] Common Toxicity Criteria [CTC] version 3 criteria) with the following exceptions: * Serum aspartate aminotransferase (AST), alanine aminotransferase (ALT), and alkaline phosphatase should be =< 5 x upper limit of normal (ULN) * Serum bilirubin =< 3 x ULN and nausea and vomiting should be =< grade 2 * Patients with myelosuppression are not excluded if absolute neutrophil count (ANC) >= 500/uL
- Platelet count should be > 50,000/ul and hemoglobin should be > 8 gm/dl; patients may receive platelet or red blood cell transfusions to maintain hemoglobin and platelets at clinical appropriate levels
- Patients with clinically suspected dense intraperitoneal adhesions preventing adequate IP distribution
- History of allergy to mouse proteins
- Patients previously treated with murine monoclonal antibodies will be excluded if they have a human anti-murine antibody (HAMA) level of > 1000 U/ml
- Active serious infections not controlled by antibiotics
- Pregnant women and women who are breast feeding are excluded; negative pregnancy test is required for all women of child-bearing age, and appropriate contraception is used during the study period; pregnancy testing will be carried out within two weeks prior to administration of radioiodinated 8H9 in females of childbearing age
- Inability or unwillingness to comply with radiation safety procedures or protocol requirements
I. Define the toxicity and maximal tolerated dose (MTD) of iodine I 131 monoclonal antibody 8H9 (131I-8H9) administered intraperitoneally.
I. Assess pharmacokinetics for intraperitoneal (IP) 131I-8H9.
II. Assess response of desmoplastic small round cell tumor (DSRCT) and other solid tumors to IP 131I-8H9.
OUTLINE: This is a dose-escalation study.
Patients receive iodine I 131 monoclonal antibody 8H9 IP on day 0.
After completion of study treatment, patients are followed up periodically.
Trial Phase Phase I
Trial Type Treatment
Memorial Sloan Kettering Cancer Center
- Primary ID 09-090
- Secondary IDs NCI-2010-01242
- Clinicaltrials.gov ID NCT01099644